Show simple item record

dc.contributor.authorJayne, David
dc.date.accessioned2021-11-19T00:30:11Z
dc.date.available2021-11-19T00:30:11Z
dc.date.issued2021-04
dc.identifier.issn0315-162X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330740
dc.description.abstractThe management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has come a long way from the first postmortem descriptions of the diseases in the 1930s and 1950s1 Pivotal phases have been the introduction of glucocorticoids (GC) and cyclophosphamide (CYC), the association with ANCA in the 1980s, and consensus classification and nomenclature systems from 1990 onwards2.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherThe Journal of Rheumatology
dc.rightsAll rights reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
dc.subjectAntibodies, Antineutrophil Cytoplasmic
dc.subjectHumans
dc.titleAntineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?
dc.typeArticle
prism.endingPage481
prism.issueIdentifier4
prism.publicationDate2021
prism.publicationNameJ Rheumatol
prism.startingPage479
prism.volume48
dc.identifier.doi10.17863/CAM.78181
dcterms.dateAccepted2021-01-20
rioxxterms.versionofrecord10.3899/jrheum.201351
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-04
dc.contributor.orcidJayne, David [0000-0002-1712-0637]
dc.identifier.eissn1499-2752
rioxxterms.typeJournal Article/Review
cam.issuedOnline2021-03
cam.orpheus.success2021-11-18 - Embargo set during processing via Fast-track
rioxxterms.freetoread.startdate2021-10-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record